Biotech

The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited incremental reaction, with the direction and magnitude of the moves dependent on the market...

Biotech stocks are off to a rough start on Thursday, especially Celgene Corporation (NASDAQ: CELG), as shares plummeted to a new 52-week low of $95.50. Celgene reported Wednesday mixed third-quarter results, but investors appear to be fixated on the company's 2020 guidance update. The company...

The single hottest large-cap exchange-traded fund, the SPDR S&P Biotech (ETF) (NYSE: XBI), is up more than 40 percent since the start of 2017 and by 10 percent in the past two weeks alone. Many investors aren't willing to assume the inherent risk that comes with investing in highly volatile...

It turns out you can have too much of a good thing. The 1,000-plus immunotherapy trials and competition to develop proprietary versions of virtually the same drugs may prove inhibitory to cancer research, according to the New York Times. The conditions leave clinical researchers competing for the...

Under a new deal between the U.S. Food and Drug Administration and the medtech device industry, manufacturers would be required to report device defects within three months of detecting their potential threat of injury ━ a tripling of the current 30-day reporting period. Events requiring recall or...

After some huge swings in the past three years, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has been relatively quiet for the past few months, trading mostly sideways within a very narrow range. The extended consolidation period may mean the IBB’s next breakout will be a big...

Cellular Biomedicine Group Inc (NASDAQ: CBMG) is a micro-cap biomedicine company focused on the development of treatments for cancerous and degenerative diseases through cell-based technologies. Last week, Benzinga attended SCN Corporate Connect’s Family Office & Life Science Symposium at...

Viridian Capital Advisors is one of the world’s leading financial and strategic advisory firms in the cannabis industry. Benzinga recently had the chance to chat with the company’s founder and president Scott Greiper, and one of its analysts, Harrison Phillips, who shared some insight...

Biotech stocks are seeking to regain some semblance of normalcy after Wednesday's Trump-inspired selloff. Much against market perceptions of a biotech-friendly President-elect Donald Trump stance, he hit out at the sector, with a vague message that suggested he is going to clamp down on drug...

Putting personal politics aside for a moment, it is not unreasonable to assume that investors who were long biotechnology stocks and exchange-traded funds into Election Day are happy with the outcome. Leading up to Election Day, Democratic nominee Hillary Clinton and her harsh rhetoric against high...

Sean Udall, CIO of Quantum Trading Strategies, was a guest in Benzinga’s PreMarket Prep show in early 2016 and predicted an S&P 500 index around 2,350 to 2,450 when most traders were calling for an S&P 500 around 1,450 to 1,600. “I stand by the call [...] I think we got a...

The past few months have been great for small cap bluebird bio Inc (NASDAQ: BLUE), which saw its stock appreciate more than 47.6 percent in the last six months and more than 31 percent in the past month alone, largely helped by the entry of its Gen2 LentiGlobin into the clinic. Benzinga recently...

A sector rotation is common, particularly in times of market volatility. However, picking the timing and the right sector is always a concern for investors. "There's always money coming out of something, going into something else," Joel Elconin, co-host of Benzinga's PreMarket Prep, said during...

Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) shares plunged nearly 9 percent in Monday's after-hours trading session following word the company may have to restate financial results, before recovering slightly. The potential restatement, according to sources, would come on the heels of a...